The discovery of the importance of the IL-36 pathway in the pathogenesis of GPP led to the development of the first specific therapeutic agent for GPP: spesolimab, an IL-36 receptor antagonist. This evidence concerns the gene IL1RL2 and psoriasis 14, pustular.